864775-63-3

Usage

Molecular Structure

1H-Pyrazolo[4,3-b]pyridine, 3-methyl-1-(triphenylmethyl)-, 4-oxide has a complex molecular structure that includes a fused pyrazole and pyridine ring, a methyl group, and a triphenylmethyl group.

Oxidized Form

The compound contains an oxygen atom in the 4th position, which gives it its oxidized form.

Usage

The chemical is utilized in various research and industrial applications, including as a building block in the synthesis of pharmaceuticals, agrochemicals, and materials science.

Potential for Therapeutic Development

Due to its unique molecular structure and properties, the compound may have potential for use in the development of new therapeutic agents.

Upstream product

• 864775-61-1 3-methyl-1-trityl-1H-pyrazolo[4,3-b]pyridine 
• 194278-45-0 3-methyl-1H-pyrazolo[4,3-b]pyridine 
• 87674-20-2 1-(3-fluoropyridin-2-yl)ethanone 

Downstream Products

• 864775-64-4 5-chloro-3-methyl-1H-pyrazolo[4,3-b]pyridine 

Relevant academic research and scientific papers

2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles

A novel series of AKT inhibitors containing 2,3,5-trisubstituted pyridines with novel azaindazoles as hinge binding elements are described. Among these, the 4,7-diazaindazole compound 2c has improved drug-like properties and kinase selectivity than those of indazole 1, and displays greater than 80% inhibition of GSK3β phosphorylation in a BT474 tumor xenograft model in mice.

INHIBITORS OF AKT ACTIVITY

Invented are novel pyridine compounds, the use of such compounds as inhibitors of PKB/AKT kinase activity and in the treatment of cancer and arthritis.